Table 2 Different drugs produce varied function in cancer
From: The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined
Drugs | Type | Main function | Functional mechanism | References |
|---|---|---|---|---|
SK1-I | Inhibitor of SphKs | Leukemia | Bcl-2 | |
Breast cancer | ERK1/2 and Akt | |||
Prostate cancer | MCF-7/MCF-7 HER2 | |||
SKI-II | Inhibitor of SphKs | Human non-small cell lung cancer | PI3K/Akt/ NF-κB | |
Estrogen receptor-regulated genes | ||||
Breast cancer therapy | SDF-1 | |||
Safingol | Putative inhibitor of SphK | Glioblastomas | A Phase I Clinical medicine | [99] |
Colorectal tumor | ||||
Adrenal cortical carcinoma | ||||
Sarcoma | ||||
ABC294640 | Selective inhibitor of SphK1 | Breast cancer | Inhibition of tumor cell migration | |
Ovarian cancer | Loss of microfilaments | |||
FTY720 | Sphingosine analog | Peripheral blood stem cell (PBSC) transplantation | Internalization and degradation of S1P receptor 1–5 | |
Immunosuppressive small molecule drug | Anti-tumor in many tissues | Bone mineral metabolism | ||
Enhanced AMD3100-mediated HSC mobilization | ||||
Needs further research | ||||
Relieved ovariectomy-induced osteoporosis | Prevent T and B cell egress from lymph nodes | |||
S1PR1↑ → SDF-1 sensitivity↑ → CXCR4↑ |